Pierce™ Bradford Protein Assay Kit
Pierce™ Bradford Protein Assay Kit
Thermo Scientific™

Pierce™ Bradford Protein Assay Kit

Pierceクマシー(Bradford)タンパク質アッセイキットは、従来のBradfordアッセイ試薬のすぐに使用できる安定した組成を持ち、総タンパク質濃度をタンパク質標準液と比較し、測定します。このキットには、クマシータンパク質アッセイ試薬とアルブミン標準アンプルのパッケージが含まれます。使用可能なすべてのBradfordアッセイの比較›Pierceクマシータンパク質アッセイキットは、もとはBradford氏が1976年に指摘した一般的なアッセイ試薬のすぐに使用できる組成を備えています詳細を見る
製品番号(カタログ番号)数量
23200950 mL
製品番号(カタログ番号) 23200
価格(JPY)
28,600
Each
お問い合わせください ›
数量:
950 mL
一括またはカスタム形式をリクエストする
Pierceクマシー(Bradford)タンパク質アッセイキットは、従来のBradfordアッセイ試薬のすぐに使用できる安定した組成を持ち、総タンパク質濃度をタンパク質標準液と比較し、測定します。このキットには、クマシータンパク質アッセイ試薬とアルブミン標準アンプルのパッケージが含まれます。

使用可能なすべてのBradfordアッセイの比較›

Pierceクマシータンパク質アッセイキットは、もとはBradford氏が1976年に指摘した一般的なアッセイ試薬のすぐに使用できる組成を備えています。酸性のクマシー色素試薬は、タンパク質溶液と混合するとサンプル中のタンパク質量に比例して茶色から青色に変色します。タンパク質測定は、タンパク質アッセイ標準液の色反応と比較して行われます。通常、ウシ血清アルブミン(BSA)またはウシガンマグロブリン(BGG)の既知の希釈液として調製されます。この簡単な手順は、試験管、キュベット、マイクロプレートなど、ほぼすべての容量スケールに適合します。このタンパク質アッセイは、タンパク質サンプル中のほとんどの塩、溶媒、バッファー、チオール、還元剤、および金属キレート剤に適合します。

クマシープロテインアッセイキットには以下の特徴があります。
Bradford試薬— 標準的なBradfordアッセイ試薬の安定したすぐに使用可能なキット
比色分析— 標準分光光度計またはプレートリーダー(595 nm)による比色測定
使いやすい— 1液タイプで試薬の調製不要
迅速—ほぼ直後に発色。追加、混合、結果の読み取り
アッセイの範囲— 1~1500 µg/mLの範囲でタンパク質濃度を検出
フレキシブル—マイクロプレートおよびキュベットプロトコルが提供され、複数のターゲット作業範囲に適合

クマシー(Bradford)アッセイによるタンパク質の検出
クマシー色素ベース(Bradford)タンパク質アッセイの発色は、タンパク質中の特定の必須アミノ酸(主にアルギニン、リジン、ヒスチジン)の存在に関連しています。ファンデルワールス力と疎水性相互作用も、タンパク質による色素の結合に関与します。各タンパク質分子に結合したクマシー色素リガンドの数は、タンパク質上で検出された陽性電荷の数にほぼ比例します。遊離アミノ酸、ペプチド、低分子量タンパク質は、クマシー色素試薬では発色しません。一般的に、この試薬でアッセイするには、ペプチドまたはタンパク質の質量が 3,000ダルトン以上である必要があります。

関連製品
Pierce クマシープラス(Bradford)アッセイ
Pierce 界面活性剤対応Bradfordアッセイキット
アンプルブレーカー
研究用途にのみご使用ください。診断目的には使用できません。
仕様
アッセイタンパク質定量アッセイ
使用対象(アプリケーション)溶液ベースの検出、吸光度
使用対象 (装置)分光光度計、マイクロプレートリーダー
製品ラインPierce
製品タイプProtein Quantitation Assay
数量950 mL
特異性非標的特異的
対応可能対象630 Tube Assays or 3800 Microplate Assays
検出法比色法
Unit SizeEach
組成および保存条件
対応範囲:
  • チューブアッセイ630回またはマイクロプレートアッセイ3,800回
  • Pierceクマシーアッセイ試薬、950 mL
  • アルブミン標準アンプル、2 mg/mL、10 x 1 mL
クマシータンパク質アッセイ試薬は4℃で保管します。未開封のアルブミン標準アンプルは室温で保管します。

よくあるご質問(FAQ)

Can you provide the shelf-life for the Pierce Bradford Protein Assay Kit?

The Pierce Bradford Protein Assay Kit is covered under our general 1-year warranty and is guaranteed to be fully functional for 12 months from the date of shipment, if stored as recommended. Please see section 8.1 of our Terms & Conditions of Sale (https://www.thermofisher.com/content/dam/LifeTech/Documents/PDFs/Terms-and-Conditions-of-Sale.pdf) for more details.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Can I purchase the Pierce Bradford Protein Assay Reagent from the Pierce Bradford Protein Assay Kit as a stand-alone product?

Sorry, the Pierce Bradford Protein Assay Reagent is only available as a component of the Pierce Bradford Protein Assay Kit.

Find additional tips, troubleshooting help, and resources within our Protein Purification and Isolation Support Center.

I assayed two protein samples, each containing a different mixture of proteins of same concentration and observed very different color responses in the assay. What is the cause?

Each of the commonly used total protein assay methods exhibits some degree of varying response toward different proteins. These differences relate to amino acid sequence, pI, structure and the presence of certain side chains or prosthetic groups that can dramatically alter the protein’s color response. Most protein assay methods use BSA or immunoglobulin (IgG) as the standard against which the concentration of protein in the sample is determined. However, if great accuracy is required, prepare the standard curve from a pure sample of the target protein.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

My buffer or components of my buffer are not listed in the compatibility table for my protein assay. What should I do?

You can test the tolerance of the assay for your specific buffer formulation. For in-house generated compatibility information, substances were considered compatible at the indicated concentration in the Standard Test Tube Protocol (found in the manual for each protein assay) if the error in protein concentration estimation caused by the presence of the substance was less than or equal to 10%. The substances were tested using WR prepared immediately before each experiment. Blank-corrected 562nm absorbance measurements (for a 1000µg/mL BSA standard + substance) were compared to the net 562nm measurements of the same standard prepared in 0.9% saline.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

All the components of my sample buffer are at or below the indicated compatible concentration for my protein assay, but I am still seeing too much/too little color development. What could be the problem?

It is possible to have a substance additive affect such that even though a single component is present at a concentration below its listed compatibility, a sample buffer containing a combination of substances could interfere with the assay. You should take steps to eliminate or minimize the effects of the interfering substance(s) by diluting or removing the substance.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

引用および参考文献 (10)

引用および参考文献
Abstract
Silibinin Ameliorates
Authors:Lee SJ, Nam MJ, Lee DE, Park JW, Kang BS, Lee DS, Lee HS, Kwon OS
Journal:Int J Mol Sci
PubMed ID:30042374
'The mechanisms underlying the progression to non-alcoholic steatohepatitis (NASH) remain to be elucidated. In the present study, we aimed to identify the proteins involved in the pathogenesis of liver tissue inflammation and to investigate the effects of silibinin, a natural polyphenolic flavonoid, on steatohepatitis. We performed comparative proteomic analysis using ... More
Versican is differentially regulated in the adventitial and medial layers of human vein grafts.
Authors:Kenagy RD, Kikuchi S, Evanko SP, Ruiter MS, Piola M, Longchamp A, Pesce M, Soncini M, Deglise S, Fiore GB, Haefliger JA, Schmidt TA, Majesky MW, Sobel M, Wight TN
Journal:PLoS One
PubMed ID:30265729
'Changes in extracellular matrix proteins may contribute significantly to the adaptation of vein grafts to the arterial circulation. We examined the production and distribution of versican and hyaluronan in intact human vein rings cultured ex vivo, veins perfused ex vivo, and cultured venous adventitial and smooth muscle cells. Immunohistochemistry revealed ... More
The Epstein-Barr virus EBNA1 protein modulates the alternative splicing of cellular genes.
Authors:Boudreault S, Armero VES, Scott MS, Perreault JP, Bisaillon M
Journal:Virol J
PubMed ID:30832682
'Alternative splicing (AS) is an important mRNA maturation step that allows increased variability and diversity of proteins in eukaryotes. AS is dysregulated in numerous diseases, and its implication in the carcinogenic process is well known. However, progress in understanding how oncogenic viruses modulate splicing, and how this modulation is involved ... More
PGC1ß regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism.
Authors:Zhang H, Li L, Chen Q, Li M, Feng J, Sun Y, Zhao R, Zhu Y, Lv Y, Zhu Z, Huang X, Xie W, Xiang W, Yao P
Journal:Mol Oncol
PubMed ID:30051603
Multiple myeloma (MM) is an incurable hematologic malignancy due to inevitable relapse and chemoresistance development. Our preliminary data show that MM cells express high levels of PGC1ß and LDHA. In this study, we investigated the mechanism behind PGC1ß-mediated LDHA expression and its contribution to tumorigenesis, to aid in the development ... More
Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes.
Authors:Saber MM, Al-Mahallawi AM, Nassar NN, Stork B, Shouman SA
Journal:BMC Cancer
PubMed ID:30111296
Colorectal cancer (CRC) remains a leading cause of death worldwide. Utilizing cisplatin in CRC is correlated with severe adverse effects and drug-resistance. Combined anticancer drug-treatment, along with, their enhanced delivery, can effectively kill cancer through multiple pathways. Nano-cubosomes are emerging as nanocarriers for anticancer therapies, hence, we constructed nano-cubosomes bearing ... More